Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Analysts offer a lukewarm endorsement to Amgen for PhIII migraine data; Arsanis raises $45.5M Series D; Covance faces restructuring
Analysts offer a lukewarm endorsement to Amgen for PhIII migraine data; Arsanis raises $45.5M Series D; Covance faces restructuring
Analysts offer a lukewarm endorsement to Amgen for PhIII migraine data; Arsanis raises $45.5M Series D; Covance faces restructuring
Submitted by
admin
on April 26, 2017 - 11:29am
Source:
Endpoints
News Tags:
migraines
Amgen
Covance
erenumab
Headline:
Analysts offer a lukewarm endorsement to Amgen for PhIII migraine data; Arsanis raises $45.5M Series D; Covance faces restructuring
Do Not Allow Advertisers to Use My Personal information
